ASP2998 + Carboplatin + ENFORTUMAB VEDOTIN + PEMBROLIZUMAB for carcinoma, transitional cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Dec 2025: Trial registered, NCT07287995
  2. 5 Feb 2026: Trial started, NCT07287995

The trials

NCT07287995: A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

State
Under way
Phase
Phase 1 and Phase 2
People
428 planned
Started
5 Feb 2026
Primary completion
30 Jun 2029
Arms
ASP2998 Combination Therapy Dose Escalation (Tumor Specific), ASP2998 Combination Therapy Dose Expansion (Tumor Specific)
Results
None posted
  1. 17 Dec 2025: Trial registered
  2. 5 Feb 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.